Vesugen

What it is

Vesugen belongs to the cytogens, the synthetic short peptides of the Khavinson school. The basic idea: short fragments that are supposed to control the respective tissue are identified from organ extracts of young animals and then reproduced chemically. For the blood vessels, this is the sequence lysine, glutamic acid, aspartic acid.

In the group’s reviews, KED stands alongside the heart peptide AEDR, better known as Cardiogen, as an active component of the peptide complexes of vessels and heart. Vesugen is not identical to Chelohart, a heart preparation made from a natural peptide complex.

Commercially, Vesugen is found mainly as a capsule product. This is remarkable because most lab experiments work with dissolved peptide applied directly to cells, and the question of how much reaches the vessel after swallowing has never been measured in humans.

How it is supposed to work

The Khavinson school describes ultrashort peptides as signaling molecules that enter the cell nucleus, bind to DNA or histones and thus change the reading of certain genes. For KED this means: genes that keep the endothelium functional are supposed to be read more strongly again in old age.

Part of this chain is measurable in the lab. In cultures of healthy, atherosclerotic and post-stent narrowed inner vessel wall, KED normalized the production of endothelin-1, a messenger that constricts vessels and is elevated in atherosclerosis. At the same time, connexin, a protein of cell-to-cell junctions, and SIRT1, an enzyme involved in DNA repair, increased. In aging endothelial cells, Ki67, connexin 43 and the vascular growth factor VEGF also increased, while the brake protein p53 decreased.

The authors interpret this as follows: atherosclerosis begins with a tired, poorly renewed inner vessel wall, and a peptide that stimulates cell renewal could intercept precisely this early stage. According to a computer model, KED fits a site in the promoter of the gene MKI67, which encodes Ki-67. This binding was not measured.

More than a vascular peptide

What is striking is how broadly KED acts in the lab. In induced nerve cells reprogrammed from skin cells of women aged 61, 66 and 68, it lengthened the dendrites overall by 42 percent and increased the number of main processes by 32 percent. In an Alzheimer’s cell model of mouse neurons, the number of mature dendritic spines rose by 20 percent, considerably less than under Pinealon with 71 percent.

In oral stem cells that had aged through many divisions, KED lowered the aging markers p16 and p21 by a factor of 1.82 to 3.23. This work comes from an Italian university group, albeit with Khavinson as co-author. Vesugen also showed effects in cultures of the pineal gland and in prostate fibroblasts.

For the assessment, this cuts both ways. On the one hand, it fits the school’s basic thesis that short peptides quite generally stimulate cell renewal in old age. On the other hand, it makes the label of vascular peptide less precise than it sounds. The literature on this is predominantly Russian and comes for the most part from the group around Khavinson himself. That does not argue against the findings, but it means that independent confirmation is still outstanding.

What the studies show

Biological age in 32 older patients (2015)

Meshchaninov and colleagues gave Vesugen and Pinealon to 32 people aged 41 to 83 with several chronic diseases and an organic psychosyndrome in remission. According to the abstract, both peptides showed a marked anabolic effect and slowed biological age, Vesugen more strongly. At the same time, the authors found pro-oxidative activity and fewer CD34-positive blood stem cells. A control group is not described; the full text is in Russian.

Blood flow in 41 men with vascular erectile dysfunction (2014)

Kitachev and colleagues, including Khavinson, treated 41 patients whose erectile dysfunction was considered a consequence of atherosclerosis with Vesugen alone. Clinical values and Doppler blood flow in the penile arteries before and after treatment were compared, with significant improvement. The title of the paper, by contrast, names circulatory disorders of the legs; title and abstract do not match.

Induced nerve cells from older female donors (2024)

Kraskovskaya and colleagues reprogrammed skin cells from three women aged 61 to 68 into nerve cells. KED lengthened the dendrites by 42 percent and increased the main processes by 32 percent. It had no measurable influence on oxidative DNA damage, mitochondria, lysosomes or the aging marker p16.

Endothelium in atherosclerosis and restenosis (2016)

Kozlov and colleagues examined KED in cultures of normal, atherosclerotic and restenotic inner vessel wall. The peptide normalized the elevated endothelin-1 production and increased connexin and SIRT1. The paper is the central support for the vascular protection thesis, but remains a cell experiment.

Where the data stop

There is no randomized, blinded or placebo-controlled trial, and there is no entry in public trial registries. The human papers are small observational studies in Russian, some combined with Pinealon, so that the share of Vesugen cannot be separated. Their endpoints are surrogates: a calculated biological age, questionnaires and ultrasound values. Whether Vesugen prevents heart attacks, strokes or vascular occlusions has not been studied by anyone. When a review by the group writes that KED normalizes blood flow in older atherosclerosis patients, it relies on precisely these papers of its own.

It is also open whether the lab findings carry over after swallowing. There are no data on absorption, distribution and breakdown in humans. Animal experiments on vascular elasticity or plaque formation, as often cited, could not be found; the only animal study with a behavioral finding concerns Alzheimer’s mice. And tissue specificity, the core promise of the bioregulators, is not strict: in the lab, KED acts on vascular, nerve, stem and prostate cells.

Status, approval and legal

Vesugen is not an approved medicine in Germany or the EU. As a food supplement it would need authorization under the Novel Food Regulation (EU) 2015/2283, which does not exist. It is sold through online vendors as a capsule product or as a research peptide. It is not on the World Anti-Doping Agency’s prohibited list by name, but as a non-approved substance it falls under group S0 and is therefore prohibited at all times in sport.

Safety

Systematic safety data do not exist. The only human paper with safety markers found, alongside the desired effects, pro-oxidative activity and a decline in CD34-positive blood stem cells, which the authors described as an inhibition of blood formation; this was not followed up. Interactions with anticoagulants, blood pressure–lowering drugs, statins or erectile dysfunction drugs have never been tested. Anyone with a vascular disease should clarify any supplement with their treating physician and not replace any prescribed therapy. There are no data for pregnancy, breastfeeding and blood disorders, and in research-grade products content and purity are untested.

Sources

• Meshchaninov et al., Adv Gerontol 2015 – Vesugen and Pinealon in 32 multimorbid patients
• Kitachev et al., Adv Gerontol 2014 – Vesugen in vascular erectile dysfunction, 41 patients
• Kozlov et al., Adv Gerontol 2016 – KED in atherosclerosis and restenosis in vitro
• Khavinson et al., Cells 2022 – SASP of cardiovascular cells and peptide regulation (review)
• Khavinson et al., Adv Gerontol 2014 – Vesugen and Ki-67 in endothelial cells
• Kraskovskaya et al., Int J Mol Sci 2024 – short peptides in induced neurons from older female donors
• Sinjari et al., Stem Cell Rev Rep 2020 – AEDG and KED against aging of oral stem cells
• Kraskovskaya et al., Bull Exp Biol Med 2017 – dendritic spines in an Alzheimer’s cell model
• ClinicalTrials.gov – search for Vesugen without any registered study
• NADA – Prohibited List 2026, informational German translation (group S0)